Aurobindo Pharma fell 2.67% to Rs 751.30 at 10:32 IST on BSE after consolidated net profit rose 33.53% to Rs 605.64 crore on 12.03% rise in total income to Rs 3783.73 crore in Q2 September 2016 over Q2 September 2015.
The result was announced on Monday, 14 November 2016, when the stock market was closed for a public holiday.Meanwhile, the S&P BSE Sensex was down 375.62 points or 1.4% at 26,443.20
On BSE, so far 1.11 lakh shares were traded in the counter as against average daily volume of 2.41 lakh shares in the past two weeks. The stock was volatile. The stock hit a high of Rs 792 and a low of Rs 738 so far during the day. The stock had hit a record high of Rs 895 on 6 October 2016. The stock had hit a 52-week low of Rs 582 on 25 February 2016.
The large-cap company has equity capital of Rs 58.52 crore. Face value per share is Re 1.
Aurobindo Pharma's consolidated earnings before interest, taxation, depreciation and amortization (EBITDA) before forex rose 19.3% to Rs 929.20 crore in Q2 September 2016 over Q2 September 2015. Consolidated EBITDA margin expanded to 24.6% in Q2 September 2016 from 23.1% in Q2 September 2015. Formulations business rose 12.4% to Rs 3004 crore in Q2 September 2016 over Q2 September 2015. API business rose 11.3% to Rs 7688 crore in Q2 September 2016 over Q2 September 2015.
N. Govindarajan, Managing Director, Aurobindo Pharma said that the company witnessed satisfactory quarter on a year on year basis with enhanced cost efficiencies. The company continues to invest for long term growth by creating niche, differentiated products using newer technologies, Aurobindo Pharma said.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The company is marketing these products globally in over 150 countries
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
